In medicated PD sufferers alexithymia has a prevalence of 21 percent and relates to melancholy. The investigation of alexithymia in newly diagnosed untreated PD patients before the administration of dopaminergic therapy is of particular medical interest due to the fact affective symptoms may precede the medical motor onset of PD. This study was aimed at investigating the prevalence of alexithymia in de novo PD patients and its relation to depression. To estimate the prevalence of alexithymia and its own relation to major depression in de novo PD sufferers the Twenty-Item Toronto Alexithymia Level and the Geriatric Depression Scale Brief Type to 42 de novo PD sufferers and 30 age-matched healthy controls had been administered.10 at 1:00 p.m. PT . The briefing will be kept in the Atlanta/Chicago area of the San Diego Marriott Marquis & Marina. The next leaders in lung tumor are scheduled to speak at the press conference: Roy Herbst, M.D., Ph.D., chief of medical oncology and associate director for translational research at the Yale Tumor Middle; David P. Carbone, M.D., Ph.D., Harold L. Moses chair in cancer analysis, director of the Specialized Plan of Analysis Excellence in Lung Cancers and co-head of the Thoracic/Mind and Neck Research Plan at the Vanderbilt-Ingram Cancer Center; and Paul A. Bunn, M.D., professor and James Dudley chair in cancer research at the University of Colorado School of Medication.